Clinical trials: Chronic Lung DIsease
Chronic Obstructive Pulmonary Disease
Effect of NVA237 on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The ability for patients with COPD to exercise is limited due to the deterioration of their lung function. NVA237 is being developed to treat COPD.
- Trial name
- GLOW3 (NCT01154127)
- Testing
- NVA237
- Where
- 10 sites in United States, Germany and 3 more
- Volunteers
- 108 people
- Sponsor
- Novartis Pharmaceuticals
COPD, Chronic Bronchitis
Airway Clearance for Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation
The purpose of this study is to show that one form of mechanical airway clearance techniques, High Frequency Chest Wall Oscillation (HFCWO)using a pneumatic vest, will diminish exacerbations of COPD which will improve respiratory…
- Conditions
- COPD, Chronic Bronchitis, Emphysema
- Trial name
- NCT00181207
- Testing
- pneumatic vest
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Johns Hopkins University
Psoriasis
A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis
The main objective of this study is to compare the effects of CP-690,550 with the effects of placebo in patients being treated for moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01276639
- Testing
- CP-690,550
- Where
- 74 sites in United States, Canada and 9 more
- Volunteers
- 901 people
- Sponsor
- Pfizer
Pulmonary Disease, Chronic Obstructive
Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients
The primary objective of this trial is to determine whether daily treatment with tiotropium (Spiriva®, Bromuro de Tiotropio®) inhalation capsule via HandiHaler® reduces the rate of decline in lung function over time in patients…
- Trial name
- NCT00144339
- Testing
- tiotropium
- Where
- 490 sites in United States, Argentina and 35 more
- Volunteers
- 5,993 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Effectiveness of Triple Therapy in COPD
To assess the effectiveness of maintenance treatment of Chronic obstructive pulmonary disease (COPD) with the Long-acting beta2-agonist - long-acting muscarinic antagonists-inhaled corticosteroids (LABA-LAMA-ICS) combination with…
- Trial name
- NCT03724877
- Testing
- Long-acting beta2-agonist-long-acting muscarinic antagonists-inhaled corticosteroids(LABA-LAMA-ICS), Long-acting beta2-agonist-inhaled corticosteroids-long-acting muscarinic antagonists (LABA-LAMA)
- Where
- United Kingdom
- Volunteers
- 8,853 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease, COPD
Nasal High Flow Therapy 30 Day Readmission Study
The aim of this feasibility study is to provide data for a subsequent randomized controlled trial to investigate if patient outcomes will be improved after an acute COPD exacerbation using domiciliary nasal high flow therapy…
- Trial name
- N3ADS (NCT02552732)
- Testing
- NHF with or without Oxygen
- Where
- 2 sites in United States, New Zealand
- Volunteers
- 29 people
- Sponsor
- Fisher and Paykel Healthcare
Chronic Graft Versus Host Disease
Extracorporeal Photopheresis and Low Dose Aldesleukin in Treating Patients With Steroid Refractory Chronic Graft-Versus-Host Disease
This phase II trial studies efficacy of extracorporeal photopheresis and low dose aldesleukin (interleukin-2) in treating patients with chronic graft-versus-host disease (cGVHD) that does not respond to upfront treatment with…
- Trial name
- NCT03007238
- Testing
- Aldesleukin, Extracorporeal Photopheresis, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- City of Hope Medical Center
Pulmonary Disease, Chronic Obstructive
Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
The aim of this First Time in Patient study is to obtain initial information on the safety, tolerability, pharmacokinetics, pharmacodynamics and clinical efficacy of repeat daily administration of danirixin in subjects with…
- Trial name
- NCT02130193
- Testing
- Danirixin
- Where
- 16 sites in United States, Germany
- Volunteers
- 102 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Trial Comparing Tiotropium Inhalation Capsules vs Placebo in Chronic Obstructive Pulmonary Disease (COPD).
A 24 week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 18mcg of tiotropium inhalation capsules administered by Handihaler once daily plus Pro Re Nata (PRN) albuterol…
- Trial name
- NCT00523991
- Testing
- tiotropium
- Where
- 62 sites in United States, Belgium and 8 more
- Volunteers
- 457 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
12 / 48 Week Pivotal PFT vs PBO in COPD I
This primary objective of this study is to compare two doses of BI 1744 CL inhalation solution delivered by the Respimat® inhaler once daily to placebo in patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00782210
- Testing
- Olodaterol (BI1744)
- Where
- 54 sites in United States, Australia and 4 more
- Volunteers
- 625 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD)
Study of Indacaterol Dosed in the Evening in Patients With Chronic Obstructive Pulmonary Disease (COPD)
This study was conducted to provide detailed information on the efficacy of indacaterol (in terms of the spirometry assessment forced expiratory volume in 1 second [FEV1]) over the full 24-h time period
- Trial name
- NCT00615030
- Testing
- Indacaterol, Salmeterol
- Where
- 7 sites in France, Germany and 1 more
- Volunteers
- 96 people
- Sponsor
- Novartis
Chronic Obstructive Pulmonary Disease (COPD)
Exercise Study in Patient With Chronic Obstructive Pulmonary Disease (0000-036)
To test the effect of the research study drug, inhaled fluticasone on lung function in exercising patients with Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT00387036
- Testing
- Fluticasone
- Volunteers
- 12 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Disease, Chronic Obstructive
A Clinical Study Assessing Critical Errors, Training/Teaching Time, and Preference Attributes of the ELLIPTA® Dry Powder Inhaler, in Comparison to Combinations of Dry Powder Inhalers Used to Provide Triple Therapy, in Patients With Chronic Obstructive Pulmonary Disease
This is a randomized, multi-centre, open-label, placebo-device, cross-over study, with a 2x2 complete block design in subjects with chronic obstructive pulmonary disease (COPD) to assess the benefits of delivering triple therapy…
- Trial name
- NCT02982187
- Testing
- PQ1
- Where
- 5 sites in Netherlands, United Kingdom
- Volunteers
- 160 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
A Study to Evaluate the Effect of the Combination of Umeclidinium (UMEC) and Vilanterol (VI) on Exercise Endurance Time (EET) in Participants With Chronic Obstructive Pulmonary Disease (COPD)
This is a multicenter, randomized, double-blind, placebo-controlled, 2-period, complete block design cross-over study. The purpose of this study is to evaluate the effect of UMEC/VI 62.5/25 microgram (mcg) on EET as measured by…
- Trial name
- NCT02275052
- Testing
- UMEC/VI DPI, Albuterol/salbutamol MDI
- Where
- 10 sites in United States
- Volunteers
- 198 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Vahelva Respimat Regulatory Post-marketing Surveillance in Korean Patients With Chronic Obstructive Pulmonary Disease
To monitor the safety profile and effectiveness of Vahelva Respimat in Korean patients with COPD in a routine clinical practice setting
- Trial name
- NCT02864407
- Testing
- Vahelva® Respimat® (Tiotropium + Olodaterol fixed dose combination)
- Where
- South Korea
- Volunteers
- 3,223 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive, Smoking
Electronic Proactive Outreach for Smokers With COPD
Chronic obstructive pulmonary disease (COPD) is one of the most common respiratory diseases, with 90% of cases directly attributable to smoking. Unfortunately, many patients continue to smoke and have an urgent need to quit.
- Trial name
- NCT04462289
- Testing
- Proactive Outreach
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- VA Office of Research and Development
Chronic Obstructive Pulmonary Disease (COPD)
A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With a Next-Generation Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
This is a 12-week (with an extension to 52 weeks in a subset of participants) study comparing the safety of BGF MDI HFO twice daily (BID) with BGF MDI HFA BID in participants with moderate to very severe COPD.
- Trial name
- NCT05573464
- Testing
- BGF MDI HFO 320/14.4/9.6 μg, BGF MDI HFA 320/14.4/9.6 μg
- Where
- 91 sites in United States, Argentina and 7 more
- Volunteers
- 559 people
- Sponsor
- AstraZeneca
Long COVID
Study of LAU-7b for the Treatment of Long COVID in Adults
ESSOR is a double-blind, placebo-controlled study of the orally-administered antiviral and inflammation-controlling LAU-7b for the treatment of adults with Long COVID and moderate to severe symptoms.
- Trial name
- ESSOR (NCT05999435)
- Testing
- LAU-7b for 3 cycles
- Where
- 5 sites in Canada
- Volunteers
- 272 people
- Sponsor
- Laurent Pharmaceuticals Inc.
Multiple Myeloma
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
The purpose of this study is to assess the safety and benefits of the investigational study drug, KW-2478, when given with bortezomib (Velcade®), a drug approved for the treatment of Multiple Myeloma (MM).
- Trial name
- NCT01063907
- Testing
- KW-2478, Bortezomib
- Where
- 26 sites in United States, Philippines and 1 more
- Volunteers
- 95 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Emphysema, Alpha 1-proteinase Inhibitor Deficiency
Extension Study of Zemaira® i.v. Administration in Subjects With Emphysema Due to alpha1-proteinase Inhibitor Deficiency.
This study is a continuation of the placebo-controlled study CE1226_4001 (NCT00261833) to evaluate the efficacy and safety of Zemaira® intravenous (i.v).
- Trial name
- NCT00670007
- Testing
- Alpha1- proteinase inhibitor [human]
- Where
- 21 sites in Australia, Canada and 9 more
- Volunteers
- 140 people
- Sponsor
- CSL Behring
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.